DocGo Inc. (DCGO) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2024
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, DocGo Inc. (DCGO) trades at a price-to-earnings ratio of 4.0x, with a stock price of $0.72 and trailing twelve-month earnings per share of $-0.45.
The current P/E is 91% below its 5-year average of 44.8x. Over the past five years, DCGO's P/E has ranged from a low of 11.1x to a high of 170.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, DCGO trades at a 83% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, DCGO trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our DCGO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Home-based care services peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
CHEChemed Corporation | $6B | 22.3 | - | -7% |
OPCHOption Care Health, Inc. | $5B | 25.4 | - | +4% |
ADUSAddus HomeCare Corporation | $2B | 19.9 | 0.99Best | +23% |
DCGODocGo Inc. | $73M | 4.0Lowest | - | +177%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | $4.24 | $0.18 | 23.4x | -48% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $3.32 | $0.29 | 11.6x | -74% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $3.09 | $0.28 | 11.1x | -75% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $4.04 | $0.20 | 20.3x | -55% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $5.59 | $0.07 | 86.0x | +92% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $5.33 | $0.07 | 75.1x | +67% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $9.37 | $0.06 | 170.4x | +280% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $8.65 | $0.18 | 46.9x | +5% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $7.07 | $0.31 | 22.8x | -49% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $9.92 | $0.43 | 23.0x | -49% |
| FY2022 Q2 | $7.14 | $0.44 | 16.3x | -64% | |
| FY2022 Q1 | $9.25 | $0.31 | 29.8x | -34% |
Average P/E for displayed period: 44.8x
See DCGO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DCGO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare DCGO vs AGIO
See how DCGO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is DCGO stock overvalued or undervalued?
DCGO trades at 4.0x P/E, below its 5-year average of 44.8x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does DCGO's valuation compare to peers?
DocGo Inc. P/E of 4.0x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is DCGO's PEG ratio?
DCGO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2024.